Real-World Evidence for the Benefits of Ramucirumab in mNSCLC

Dear Dr. Renukaprasad A R, Ramucirumab, in combination with docetaxel, is indicated for locally advanced or metastatic non-small cell lung cancer (mNSCLC) patients with disease progression on or after platinum-based chemotherapy. Join us TODAY at 04:30 PM and 09:30 PM IST to get more insights on ramucirumab as a second-line treatment option for mNSCLC following immune checkpoint inhibitors and chemotherapy! Looking forward to your active participation in the discussion! Highlights: Opening remarks - Prof. Marwan Ghosn Second-line treatment option for mNSCLC patients following chemotherapy and immune checkpoint inhibitor: Analysis from German hospitals - Prof. Claas Wesseler Clinical case presentation - Dr. Emad Anwar Panel discussion - Moderator:Dr. Shyam Aggarwal Join Now Docplexus: One of the world's largest online communities of Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*